Immunitybio Stock Revenue
| IBRX Stock | USD 5.04 0.06 1.18% |
Immunitybio fundamentals help investors to digest information that contributes to Immunitybio's financial success or failures. It also enables traders to predict the movement of Immunitybio Stock. The fundamental analysis module provides a way to measure Immunitybio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunitybio stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 622 K | 617.8 K |
Immunitybio | Revenue |
Immunitybio Company Revenue Analysis
Immunitybio's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Immunitybio Revenue | 622 K |
Most of Immunitybio's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunitybio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Immunitybio
Projected quarterly revenue analysis of Immunitybio provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Immunitybio match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Immunitybio's stock price.
Immunitybio Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Immunitybio is extremely important. It helps to project a fair market value of Immunitybio Stock properly, considering its historical fundamentals such as Revenue. Since Immunitybio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunitybio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunitybio's interrelated accounts and indicators.
| 0.0 | -0.82 | -0.36 | 0.87 | 0.51 | ||
| 0.0 | -0.03 | -0.48 | 0.07 | 0.64 | ||
| -0.82 | -0.03 | 0.29 | -0.66 | -0.32 | ||
| -0.36 | -0.48 | 0.29 | -0.34 | -0.71 | ||
| 0.87 | 0.07 | -0.66 | -0.34 | 0.51 | ||
| 0.51 | 0.64 | -0.32 | -0.71 | 0.51 |
Click cells to compare fundamentals
Immunitybio Revenue Historical Pattern
Today, most investors in Immunitybio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immunitybio's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Immunitybio revenue as a starting point in their analysis.
Immunitybio Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Immunitybio Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Immunitybio reported 622 K of revenue. This is 99.99% lower than that of the Biotechnology sector and 99.92% lower than that of the Health Care industry. The revenue for all United States stocks is 99.99% higher than that of the company.
Immunitybio Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunitybio's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunitybio could also be used in its relative valuation, which is a method of valuing Immunitybio by comparing valuation metrics of similar companies.Immunitybio is currently under evaluation in revenue category among its peers.
Immunitybio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunitybio from analyzing Immunitybio's financial statements. These drivers represent accounts that assess Immunitybio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunitybio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.5B | 5.1B | 2.4B | 2.0B | 2.6B | 2.7B | |
| Enterprise Value | 1.5B | 5.3B | 2.8B | 2.6B | 3.0B | 2.8B |
Immunitybio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunitybio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunitybio's managers, analysts, and investors.Environmental | Governance | Social |
Immunitybio Institutional Holders
Institutional Holdings refers to the ownership stake in Immunitybio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immunitybio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunitybio's value.| Shares | Bank Of America Corp | 2024-06-30 | 958.5 K | First Trust Advisors L.p. | 2024-06-30 | 887.6 K | Allen Holding Inc | 2024-09-30 | 687.6 K | Sheets Smith Wealth Management | 2024-09-30 | 666 K | Bank Of New York Mellon Corp | 2024-06-30 | 621.5 K | Accurate Wealth Management, Llc | 2024-09-30 | 560 K | D. E. Shaw & Co Lp | 2024-09-30 | 520.1 K | Bsc Private Wealth Management, Llc | 2024-09-30 | 482.5 K | Royal Bank Of Canada | 2024-06-30 | 470.2 K | Vanguard Group Inc | 2024-09-30 | 16.9 M | Blackrock Inc | 2024-06-30 | 11.4 M |
Immunitybio Fundamentals
| Return On Asset | -0.56 | ||||
| Operating Margin | (13.14) % | ||||
| Current Valuation | 4.12 B | ||||
| Shares Outstanding | 696.83 M | ||||
| Shares Owned By Insiders | 77.00 % | ||||
| Shares Owned By Institutions | 10.11 % | ||||
| Number Of Shares Shorted | 52.75 M | ||||
| Price To Sales | 479.00 X | ||||
| Revenue | 622 K | ||||
| Gross Profit | 240 K | ||||
| EBITDA | (436.18 M) | ||||
| Net Income | (583.2 M) | ||||
| Cash And Equivalents | 82.94 M | ||||
| Cash Per Share | 0.21 X | ||||
| Total Debt | 726.72 M | ||||
| Current Ratio | 0.31 X | ||||
| Book Value Per Share | (1.07) X | ||||
| Cash Flow From Operations | (366.76 M) | ||||
| Short Ratio | 7.13 X | ||||
| Earnings Per Share | (0.90) X | ||||
| Price To Earnings To Growth | 3.69 X | ||||
| Target Price | 14.25 | ||||
| Number Of Employees | 672 | ||||
| Beta | -0.43 | ||||
| Market Capitalization | 3.51 B | ||||
| Total Asset | 504.45 M | ||||
| Retained Earnings | (2.96 B) | ||||
| Working Capital | 235.8 M | ||||
| Net Asset | 504.45 M |
About Immunitybio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunitybio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunitybio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunitybio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.